The charges claim Apotex worked with other drug companies to increase and maintain the price of pravastatin, a cholesterol drug that lowers the risk of heart disease and stroke, from 2013 to 2015.
Apotex agreed to pay $24.1 million as part of a deferred prosecution agreement. Under the agreement, Apotex is required to cooperate with the government’s broader investigation into generic drug pricing and put in place a program to detect and prevent future antitrust violations.
In return, the Justice Department will defer any prosecution for three years and drop the price-fixing charge if Apotex cooperates.
Read the full news release here.
More articles on pharmacy:
CVS’ goal of opening 1,500 HealthHubs on track despite pandemic
FDA adds heartburn drug being tested to treat COVID-19 to shortage list
Drug transport costs jump 224% amid COVID-19 pandemic, survey finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.